Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2011-03-22
2011-03-22
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S441000, C514S161000, C514S162000, C549S036000, C549S037000, C562S426000
Reexamination Certificate
active
07910568
ABSTRACT:
The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention/treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention/treatment of colon cancer.
REFERENCES:
patent: 4412992 (1983-11-01), Chan et al.
patent: 4440763 (1984-04-01), Lover
patent: 5013727 (1991-05-01), Halskov
patent: 6197341 (2001-03-01), Freiss et al.
patent: 6458776 (2002-10-01), Ekwaribe et al.
patent: 6602915 (2003-08-01), Uhrich et al.
patent: 7498355 (2009-03-01), Wallace et al.
patent: 2204747 (1997-03-01), None
patent: 6400267 (1964-07-01), None
patent: WO2005072113 (2005-08-01), None
patent: WO2006037623 (2006-04-01), None
patent: WO2006066894 (2006-06-01), None
Vaidyanathan et al., 1964, CAS: 62:30051.
Pellicciari, et al., “Brush-Border-Enzyme-Mediated Intestine-Specific Drug Delivery. Amino Acid Prodrugs of 5-Aminosalicylic Acid”, J. Med. Chem, 1993, vol. 36, pp. 4201-4207.
Distrutti, et al., “Evidence That Hydrogen Sulfide Exerts Antinocicieptive Effects in the Gastrointestinal Tract by Activating KATP Channels”, J. Pham. and Exp. Ther., 2005, vol. 316, pp. 325-335.
Teague, et al., “The Smooth Muscle Relaxant Effect of Hydrogen Sulfide In Vitro: Evidence for a Physiological Role to Control Contractility”, British Journal of Pharmacology, 2002, vol. 137, pp. 139-145.
Dzierzewicz, et. al., “Susceptibility of Desulfovibrio Desulfuuricans Intestinal Strains to Sulfasalazine and its Biotransformation Products”, Med. Sci. Monit., 2004, vol. 10, No. 6, BR185-190.
Edmond, et al., “The Effect of 5-aminosalicylic Acid-containing Drugs on Sulfide Production by Sulfate-reducing Bacteria and Amino Acid-fermenting Bacteria”, Inflammatory Bowel Diseases, 2003, vol. 9, No. 1, pp. 10-17.
Fiorucci, et al., “Inhibition of Hydrogen Sulfide Generation Contributes to Gastric Injury Caused by Anti-Inflammatory Nonsteroidal Drugs”, Gastroenterology, Oct. 2005, vol. 129, No. 4, pp. 1210-1224.
Sidhu, et al., “L-Cysteine and Sodium Hydrogen sulfide Inhibit Spontaneous Contractibility in Isolated Pregnant Rat Uterine Strips in Vivo”, Pharmacology & Toxicology, 2001, vol. 88, pp. 198-203.
Zhao, et al., “The Vasorelaxant Effect of H2S as a Novel Endogenous Gaseous KATP Channel Opener”, EMBO Journal, 2001, vol. 20, No. 21, pp. 6008-6016.
Zhao, et al., “H2S—Induced Vasolrelaxation and Underlying Cellular and Molecular Mechanisms”, Am. J. Physiol. Heart Circ. Physiol., 2002, vol. 283, pp. H474-480.
Abe, et al., “The Possible Role of Hydrogen Sulfide As An Endogenous Neuromodular”, The Journal of Neuroscience, 1996, vol. 16, No. 3, pp. 1066-1071.
Carceller, et al., “Novel Azo Derivatives As Prodrugs of 5-Aminosalicylic Acid and Amino Derivatives with Potent Platelet Activating Factor Antagonist Activity”, J. Med. Chem., 2001, vol. 44, No. 18, pp. 3001-3013.
Fujii, et al., “Hydrogen Sulfide as an Endogenous Modular of Biliary Bicarbonate Excretion in the Rat Liver”, Antioxidants & Redox Signaling, 2005, vol. 7, Nos. 5 & 6, pp. 788-794.
Pitcher, M.C.L, et al., “The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis”, Gut, 2000, vol. 46, pp. 64-72.
Xu, Xi-Ming, et al., “Effects of garlicin on apoptosis in rat model of colitis”, World J Gastoenterol, Aug. 7, 2005, vol. 11(29), pp. 4579-4582.
Galvez, Julio, et al., “Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat”, British Journal of Pharmacology, 2000, vol. 130(8), pp. 1949-1959.
Wahl, Christian, et al., “Sulfasalazine: a potent and specific inhibitor of nuclear factor Kappa B”, The American Society for Clinical Investigation, Inc., Mar. 1998, vol. 101(5), pp. 1163-1174.
Bai, Ai-Ping, et al., “Dially trisulfide inhibits tumor necrosis factor-alpha expression in inflammed mucosa of ulcerative colitis”, Digestive Diseases and Sciences, Aug. 2005, vol. 50(8), pp. 1426-1431.
Li, Ling, et al., “Hydrogen sulphide—a novel mediator of inflammation?”, Current Opinion in Pharmacology, 2006, vol. 6, pp. 125-129.
Ohge, Hiroki, et al., “Association between fecal hydrogen sulfide production and pouchitis”, Dis Colon Rectum, Mar. 2005, vol. 48(3), pp. 469-475.
Schmedes, Anne, et al., “Low S-adenosylmethionine concentrations found in patients with severe inflammatory bowel disease”, Clin Chem Lab Med, 2004, vol. 42(6), pp. 648-653.
Wang, Rui, “Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?”, FASEB Journal, Nov. 2002, vol. 16, pp. 1792-1798.
Aharonowitz, et al., “Characterization of a broad-range disulfide reductase fromStreptomyces clavuligerusand its possible role in B-lactum antibiotic biosynthesis”, Journal of Bacteriology, 1993, vol. 175, pp. 623-629.
Caliendo Giuseppe
Cirino Giuseppe
Fiorucci Stefano
Santagada Vincenzo
Sparatore Anna
Antibe Therapeutics Inc.
Bennett Jones LLP
Shiao Rei-tsang
LandOfFree
Derivatives of 4- or 5-aminosalicylic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of 4- or 5-aminosalicylic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 4- or 5-aminosalicylic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694299